49% Increase in Revenue compared to the same Period in the Prior Year


TORONTO, Oct. 01, 2018 — Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company”) is
pleased to report its financial results for the three months ending July 31, 2018. All amounts are stated in thousands of
Canadian dollars.

Financial Highlights:
• Cash position was $5,844 compared to $8,953 as at April 30, 2018. During the quarter, a $588 licensing fee was paid to
Medicine Man Technologies, capital expenditures on the production facility were $379 and working capital declined by
• Working capital was $4,491 compared to $6,670 as at April 30, 2018
• Revenue for the three months ending July 31, 2018 was $1,231, an increase of $405 or 49% compared to $826 in the
prior year
• EBITDAS (1) for the three months ending July 31, 2018 was a deficit of ($906) during the three months ending July 31,
2018, a 15% improvement compared to ($1,060) in the prior year
• Loss and Comprehensive loss for the year was ($2,028) for the three months ending July 31, 2018 compared to
($1,580) for the same period in the prior year
(1) “EBITDAS” is comprised of Loss and Comprehensive Loss for the Year plus Depreciation and amortization plus
Interest, Taxes, Impairment and Stock Based Compensation. EBITDAS is considered by the Company to be a useful
measure of cash-flow from operations.

“The increase in revenue compared to the same quarter last year shows our medical cannabis clinic model is working,” says
Chris Churchill-Smith, CEO. “During the last few months we have increased clinic efficiency and expect to make further
improvements as a result of our proprietary clinic software resulting in further and sustained growth to our patient base. We
have expanded the number of Licensed Producers servicing our clients and will soon be able to offer our own brand of cannabis
tailored to their individual needs which will dramatically improve Canada House’s profitability on a go-forward basis.” concludes
Mr. Churchill-Smith.

Business Highlights for the Quarter:

• Appointed a new President of Marijuana for Trauma (“MFT”)
• Abba Medix Corp. (“Abba”) completed its Health Canada pre-sales inspection and received an amendment to its
Producer’s Licence from Health Canada to include the sale and provision of cannabis seeds
• Through its wholly owned subsidiary Abba Medix Corp., entered into an exclusive licensing agreement with Medicine
Man Technologies Inc. for deployment of its intellectual property and product lines (Three a Light®, Success
Nutrients®, General Intellectual Property) into the Canadian marketplace.
• Signed a Memorandum of Understanding (MOU) with The University of New Brunswick (UNB) to provide researchers
with opportunities to pursue the health benefits of cannabis.
• Abba Medix Corp. (“Abba”) subsidiary planted its first crop of high grade medicinal cannabis seeds at the Company’s
Health Canada Licensed (LP) Pickering grow facility. Eight strains were chosen for this first planting to meet the
medicinal needs of its sister firm Marijuana for Trauma (“MFT”) and their thousands of clients across Canada.

Canada House Wellness Group Inc.

Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The
Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully
integrated cannabis therapy company. For more information please visit https://www.canadahouse.ca or www.sedar.com.

For further information, please contact:

Boom Capital Markets
Steve Low

Canada House Wellness Group Inc.
Chris Churchill-Smith

Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements,
including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its
future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can
generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”,
“intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and
expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking
statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on
such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in such statements. Material assumptions used to develop
forward-looking information in this news release include, among other things, the regulations related to cannabis use under the
Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs
and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal
for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional
capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market;
the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material
factors that could cause actual results to differ materially from expectations and about material factors or assumptions
applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s
Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian
securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the
forward-looking statements contained in this document, whether as a result of new information, future events or otherwise,
except as required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility
for the adequacy or accuracy of this release.